| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -48.1 | -32.6 |
| EPS (diluted, $ a share) | $-0.44 | $-0.33 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ORIC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Oric Pharmaceuticals, Inc.: key numbers
- Share price
- $7.52Close, Nov 16
- Market cap
- $782M
- Shares outstanding
- 103.93MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Oric Pharmaceuticals, Inc.
All →Oric Pharmaceuticals Financial Results
ORIC Pharmaceuticals reported third quarter 2026 financial results and provided updates on its late-stage oncology portfolio, including the initiation of the Himalayas-1 Phase 3 trial for rinzimetostat in prostate cancer. The company ended the quarter with $345 million in cash and investments, which is expected to fund operations into the second half of 2028.
“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC.”
Jacob M. Chacko, M.D., president and chief executive officer
“With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”
Jacob M. Chacko, M.D., president and chief executive officer
Oric Pharmaceuticals Clinical Trial Data
ORIC Pharmaceuticals reported updated Phase 1b data for enozertinib (ORIC-114) in patients with EGFR-mutant non-small cell lung cancer, showing an 84% confirmed systemic objective response rate. The data, presented at the ESMO Congress 2026, also highlighted significant intracranial activity and plans to initiate a global Phase 3 registrational trial in the first half of 2027.
Oric Pharmaceuticals CFO Dominic Piscitelli Sells $189K of Stock
Dominic Piscitelli, CFO, sold 14,000 shares of Oric Pharmaceuticals, Inc. at $13.53 a share, worth $189K in total on Oct 20, 2026. Shares held after the trade: 69,828 (-16.7%).
- Value
- $189K
- Shares
- 14,000
- Price
- $13.53
- Role
- CFO
- Holding change
- -16.7%
- Trade date
- Oct 20, 2026
Oric Pharmaceuticals Director Richard A. Heyman Sells $86.5K of Stock
Richard A. Heyman, Director, sold 6,700 shares of Oric Pharmaceuticals, Inc. at $12.91 a share, worth $86.5K in total on Oct 1, 2026. Shares held after the trade: 203,472 (-1.5%).
- Value
- $86.5K
- Shares
- 6,700
- Average price
- $12.91
- Role
- Director
- Holding change
- -1.5%
- Trade date
- Oct 1, 2026